2 Information about certolizumab pegol
|
Marketing authorisation indication |
Certolizumab pegol (Cimzia; UCB Pharma) is indicated 'for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'. |
|---|---|
|
Dosage in the marketing authorisation |
Loading dosage The recommended starting dosage of certolizumab pegol for adults is 400 mg (given as 2 subcutaneous injections of 200 mg each) at weeks 0, 2 and 4. Maintenance dosage The maintenance dosage of certolizumab pegol for adults is 200 mg every 2 weeks. A dosage of 400 mg every 2 weeks can be considered when there is an insufficient response. Available data in adults with plaque psoriasis suggest that there is usually a clinical response within 16 weeks of treatment. Continued treatment should be carefully reconsidered in people whose psoriasis shows no evidence of therapeutic benefit within the first 16 weeks of treatment. Sometimes, when there is an initial partial response, it may subsequently improve with continued treatment beyond 16 weeks. |
|
Price |
£357.50 per 200 mg pre-filled pen or syringe (excluding VAT, British national formulary online; accessed February 2019). The company has a commercial arrangement. It is the company's responsibility to let relevant NHS organisations know details of the arrangement. |